Business Description
Amgen Inc
NAICS : 325412
SIC : 2834
ISIN : US0311621009
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | 0.07 | |||||
Debt-to-Equity | 10.57 | |||||
Debt-to-EBITDA | 5.3 | |||||
Interest Coverage | 1.93 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.46 | |||||
Beneish M-Score | -2.26 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.7 | |||||
3-Year EBITDA Growth Rate | 7.7 | |||||
3-Year EPS without NRI Growth Rate | 14.9 | |||||
3-Year FCF Growth Rate | -6.6 | |||||
3-Year Book Growth Rate | -10.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 4.77 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.81 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.26 | |||||
Quick Ratio | 0.89 | |||||
Cash Ratio | 0.43 | |||||
Days Inventory | 233.01 | |||||
Days Sales Outstanding | 77.76 | |||||
Days Payable | 51.79 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Payout Ratio | 0.52 | |||||
3-Year Dividend Growth Rate | 10 | |||||
3-Year Average Share Buyback Ratio | 2.5 | |||||
Shareholder Yield % | -4.63 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 63.3 | |||||
Operating Margin % | 20.02 | |||||
Net Margin % | 10.12 | |||||
FCF Margin % | 17.72 | |||||
ROE % | 49.5 | |||||
ROA % | 3.39 | |||||
ROIC % | 9.25 | |||||
3-Year ROIIC % | -5.19 | |||||
ROC (Joel Greenblatt) % | 95.2 | |||||
ROCE % | 9.15 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 55.46 | |||||
Forward PE Ratio | 12.38 | |||||
PE Ratio without NRI | 19.11 | |||||
Shiller PE Ratio | 27.21 | |||||
Price-to-Owner-Earnings | 41.17 | |||||
PEG Ratio | 3.47 | |||||
PS Ratio | 5.61 | |||||
PB Ratio | 29.2 | |||||
Price-to-Free-Cash-Flow | 31.69 | |||||
Price-to-Operating-Cash-Flow | 26.94 | |||||
EV-to-EBIT | 33.62 | |||||
EV-to-Forward-EBIT | 13.01 | |||||
EV-to-EBITDA | 19.18 | |||||
EV-to-Forward-EBITDA | 10.28 | |||||
EV-to-Revenue | 7.32 | |||||
EV-to-Forward-Revenue | 6.18 | |||||
EV-to-FCF | 41.32 | |||||
Price-to-Projected-FCF | 1.73 | |||||
Price-to-DCF (Earnings Based) | 1.1 | |||||
Price-to-DCF (FCF Based) | 2.42 | |||||
Price-to-Median-PS-Value | 1.01 | |||||
Earnings Yield (Greenblatt) % | 2.97 | |||||
FCF Yield % | 3.17 | |||||
Forward Rate of Return (Yacktman) % | 9.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Amgen Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 30,934 | ||
EPS (TTM) ($) | 5.81 | ||
Beta | 0.02 | ||
Volatility % | 1.48 | ||
14-Day RSI | 0 | ||
14-Day ATR ($) | 0 | ||
20-Day SMA ($) | 255.16 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 255.16 - 255.16 | ||
Shares Outstanding (Mil) | 537.33 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Amgen Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Amgen Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Amgen Inc Frequently Asked Questions
What is Amgen Inc(XSGO:AMGN)'s stock price today?
When is next earnings date of Amgen Inc(XSGO:AMGN)?
Does Amgen Inc(XSGO:AMGN) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |